11 completed, 2 no longer available, 1 recruiting, 1 terminated. 13 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 10, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 3 | Completed 3 |
Follow Andrei Iagaru: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC 89Zr-panitumumab IV, Panitumumab - Head-and-neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Andrei Iagaru | 2026-06-01 | 2026-08-17 | |
| 99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT 18Fluorocholine - Parathyroid Adenoma | Phase 2 / Phase 3 | Recruiting | Andrei Iagaru | 100 | 2023-09-27 | 2026-06-24 |
| Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2 - Prostate Adenocarcinoma, PSA Progression | Phase 2 | Completed | Andrei Iagaru | 27 | 2020-12-15 | 2024-01-30 |
| HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer 68-Ga RM2., 68-Ga PSMA11, PET/MRI - Prostate Cancer | Phase 2 | Terminated | Andrei Iagaru | 4 | 2020-02-05 | 2024-02-01 |
| 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy 68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan - Prostate Cancer | Phase 1 / Phase 2 | Completed | Andrei Iagaru | 14 | 2019-04-09 | 2024-01-30 |
| 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, Positron Emission Tomography - Breast Carcinoma, Estrogen Receptor Positive | Phase 1 / Phase 2 | Completed | Andrei Iagaru | 5 | 2019-03-19 | 2023-12-13 |
| 18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392 - Cigarette Smoker, Current Smoker | Phase 2 | Completed | Andrei Iagaru | 15 | 2019-02-04 | 2025-04-09 |
| 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer 68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software - Prostate Cancer | Phase 2 | Completed | Andrei Iagaru | 14 | 2019-01-14 | 2024-01-11 |
| Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS) - Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck | Phase 1 | Completed | Andrei Iagaru | 14 | 2019-01-07 | 2023-05-19 |
| 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET) - Prostate Adenocarcinoma, PSA Failure | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 61 | 2017-05-20 | 2022-01-13 |
| 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis - Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 | Completed | Andrei Iagaru | 44 | 2017-04-10 | 2023-12-12 |
| 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery 68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET) - Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 74 | 2016-04-18 | 2022-03-04 |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography - Prostate Adenocarcinoma | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 122 | 2015-11-16 | 2023-04-10 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy 18F-FSPG, 18F-FDG - B-Cell Neoplasm, Estrogen Receptor Negative | Phase 2 | Completed | Andrei Iagaru | 7 | 2015-07-01 | 2019-01-03 |
| 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors 68Ga-DOTA TATE - Carcinoid Tumors, Islet Cell (Pancreatic NET) | No longer available | Andrei Iagaru | 2017-08-23 | |||
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis - Prostate Adenocarcinoma, PSA Level Greater Than 0.2 | No longer available | Andrei Iagaru | 2022-01-21 |
Prostatic Neoplasms (6) · Breast Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenoma, Islet Cell (1) · Carcinoid Tumor (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Head and Neck Neoplasms (1) · Lymphoma, B-Cell (1) · Mesothelioma (1) · Multiple Pulmonary Nodules (1) · Parathyroid Neoplasms (1) · Smoking Cessation (1) · Triple Negative Breast Neoplasms (1)
Magnetic Resonance Spectroscopy (7) · BAY 86-7548 (6) · gallium 68 PSMA-11 (5) · 4-(3-fluoropropyl)glutamic acid (2) · Fluorodeoxyglucose F18 (2) · Panitumumab (2) · (4S)-4-(3-(18F)fluoropropyl)-L-glutamate (1) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · 68Ga-bombesin (1) · Diagnostic Imaging (1) · Gallium (1) · Positron Emission Tomography Computed Tomography (1) · Positron-Emission Tomography (1) · Receptors, Bombesin (1) · Tomography (1)
United States (16)
Andrei H Iagaru, MD (3) · Andrei M Iagaru, MD (1) · Carina Mari Aparici (1) · Fred Baik, MD (1)
PMID 33674398, PMID 34406051, PMID 37555901, PMID 31478089, PMID 36328488, PMID 36396456, PMID 38423030, PMID 38664016
P30CA124435 (2), R01CA190306 (1), R01CA230438 (1)